Funder
National Cancer Institute
Pennsylvania Department of Health
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Curran WJ Jr, Paulus R, Langer CJ et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103(19):1452–1460
2. Hillner BE (1995) Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592). J Natl Cancer Inst Monogr 19:65–67
3. Evans WK, Will BP, Berthelot JM, Earle CC (1997) Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 15(9):3038–3048
4. Thongprasert S, Permsuwan U, Ruengorn C, Charoentum C, Chewaskulyong B (2011) Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer. Asia Pac J Clin Oncol 7(4):369–375
5. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics 29(12):1051–62
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献